Our overview of yield stocks worth considering topped last week's most read articles followed by a look at Ramsay Health Care and the challenges it faces, and the impact healthcare costs are having on retiree budgets.  

5 yield stocks worth considering

These companies spanning the automotive and financial services sectors are tipped to deliver solid dividend yields over at least the next two years.

Industry woes weigh on Ramsay

Australia's largest private hospital operator, Ramsay Health Care (ASX: RHC) has reported a 6.8 per cent rise in underlying net profit of $579.3 million for fiscal 2018.  

Climbing healthcare costs squeeze retirees

Australian retirees are feeling the financial pinch as they face increases in the cost of health services, transport, and clothing, according to research from Australia’s peak superannuation body. 

G8 Education's profit loss not a disaster, says Morningstar

The childcare centre operator reported a $25.6 million in net profit for the first half of fiscal 2018, down 24 per cent from $33.7 million last year. 

Is your super fund performing?

There are two reasons you could be losing money in your super; the eroding impact of fees, or poor performance.

TPG-Vodafone merger a positive for incumbents, says Morningstar

The announcement of a $15 billion merger between Vodafone Australia and TPG Telecom (ASX: TPM) would benefit Australia's telco sector, according to Morningstar's Brian Han.

Investing Basics: Are you paying too much for your super?

As superannuation members, we want to steer clear of high fees and lousy performance. We rely on our super to provide in retirement – without this pot we potentially face poverty as pensioners.

2 moat stocks riding tech rally

These Australian-domiciled software companies delivered solid results this earnings season, in a tech sector that continues to prioritise revenue over profit.

Westpac blinks first amid loan funding pressure

Westpac has become the first of the big four banks to raise interest rates, staging a 14-basis point rise, amid a record period of inertia by the Reserve Bank of Australia.

Positive outlook despite Mayne's $134m full-year loss

The specialty drug-maker exceeded analysts' expectations on an adjusted basis, despite posting a full-year loss of $133.98 million.

   

More from Morningstar

• Global Market Report - 3 September

• Transurban wins in $9.3bn WestConnex deal

• Make better investment decisions with Morningstar Premium | Free 4-week trial

 

Lex Hall is a Morningstar content editor, based in Sydney.

© 2018 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO"). The article is current as at date of publication.